Entries by Philip Rye
AlgiPharma registers new company in Australia
AlgiPharma has registered a new proprietary limited company in Melbourne, Australia.
AlgiPharma’s Cystic Fibrosis drug candidate OligoG awarded pivotal trial grant of €6 million from EU’s Horizon 2020 programme
An EU Horizon 2020 proposal (OligoGpivotalCF) submitted by a consortium assembled by AlgiPharma, has been successful in winning a grant of EUR 6 million to support AlgiPharma’s cystic fibrosis drug candidate OligoG through a pivotal clinical trial program.
AlgiPharma receives up to an additional $3 million from the US Cystic Fibrosis Foundation (CFF)
AlgiPharma AS announced an agreement with Cystic Fibrosis Foundation (CFF), Bethesda, MD., that will provide up to $3 million to support further research and development of AlgiPharma’s drug candidate (OligoG) for the treatment of people with cystic fibrosis. This is in addition to more than $11.5 million already received from the Cystic Fibrosis Foundation for Phase 2 clinical work.
AlgiPharma awarded 4 year grant from the Norwegian Research Council’s NANO2021 programme
AlgiPharma has been awarded up to NOK 10 million from the Norwegian Research Council for the project “Novel alginate oligomer products for enhanced delivery across mucosal barriers (Mucos-ALG)”.
Hilde Morris joins AlgiPharma
Hilde Morris has recently been appointed to replace our outgoing clinical director.
AlgiPharma collaboration with Cardiff University wins Medical Innovation Award
AlgiPharma collaboration wins Cardiff University’s prestigious Medical Innovation Award
AlgiPharma Announces $4 Million Award from Cystic Fibrosis Foundation Therapeutics to Advance Clinical Development of OligoG
AlgiPharma Announces $4 Million Award from Cystic Fibrosis Foundation Therapeutics to Advance Clinical Development of OligoG.
AlgiPharma features in CFF drug development pipeline
AlgiPharma now features on the Cystic Fibrosis Foundation (CFF) drug development pipeline
AlgiPharma signs new license agreement with NTNU
AlgiPharma secures new license agreement with NTNU for exclusive global rights.
